-
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)
What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Preeclampsia & immune cell regulation | Assay Genie(Post)What is preeclampsia? According to the World Health Organization (WHO), one in ten pregnant women is affected by hypertensive disorders, and preeclampsia a
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
Growth Factors Can Cooperate to Promote Tumorigenesis(Post)Introduction Tumorigenesis, the process by which normal cells transform into cancer cells, is a multifaceted and complex event influenced by various internal and external factors. Among the
Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Agarose vs Polyacrylamide: A Comparative Analysis(Post)Techniques · Gel ElectrophoresisAgarose vs Polyacrylamide: A Comparative AnalysisAgarose and polyacrylamide are the two workhorse gel matrices of electrophoresis. Agarose gels resolve larger DNA and R
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
Build a science blog to progress your career(Post)What do scientists consider their skill set when looking for jobs outside of academia? Mine where hard to sum. I was a PhD in cell biology. I could Western Blot, I had used thousands of anti
PharmaGenie ELISA キット(Page)PharmaGenie ELISA キット | Assay Genie | Assay Genie
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Epigenetic Antibodies(Page)Epigenetic Antibodies | 81+ Histone Acetylation & Methylation Antibodies | Assay Genie
Introducing BioSymposia: The Gathering Place for Science(Post)Announcement · Powered by Assay GenieIntroducing BioSymposia: The Gathering Place for ScienceWe’re excited to announce the launch of BioSymposia, our new sister platform and a free home for scientific
No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
TNF Receptor Superfamily: TNFR1 vs TNFR2(Page) Androgenic steroid action in breast cancer(Post)By Rachel Bleach, PhD Student, RCSI By the age of 79 years, 1 in 14 women will develop breast cancer (Global Burden of Disease Cancer 2017). Beatson reported